UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2022

 

Commission File Number: 001-38064

 

Aeterna Zentaris Inc.

(Translation of registrant’s name into English)

 

c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 

 

 

 

DOCUMENTS INDEX

 

Exhibit   Description
99.1   Press Release dated April 19, 2022 regarding New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

 

( 2 )

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    AETERNA ZENTARIS INC.
       
Date: April 19, 2022   By: /s/ Klaus Paulini
      Klaus Paulini
      President and Chief Executive Officer

 

( 3 )

 

 

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Aeterna Zentaris Charts.
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Aeterna Zentaris Charts.